Drugs / Larsucosterol
Larsucosterol
also known as
DUR 928 · 25HC3S · DUR-928 sodium · DV-928 · DV-928 SODIUM · LARSUCOSTEROL SODIUM · Sodium larsucosterol
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT04563026 | Jan 2021 → Sep 2023 | alcoholic hepatitis | Durect | Completed | Missed primary |
| Phase 2 | NCT04447404 | Sep 2020 → Mar 2021 | COVID-19 | Durect | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03837743 | Feb → Nov 2019 | psoriasis | Durect | Completed | Missed primary |
| Phase 2 | NCT03432260 | Apr 2018 → Sep 2019 | alcoholic hepatitis | Durect | Completed | No outcome recorded |
| Phase 2 | NCT03394781 | Jan 2018 → Jan 2019 | primary sclerosing cholangitis | Durect | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT07428538 | Jan 2026 → Nov 2027 expected | hepatitis | Bausch Health Americas, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03917407 Comparator | Jun 2021 → Sep 2023 | alcoholic hepatitis | Craig James McClain | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Larsucosterol | “This study is to evaluate the safety and pharmacokinetics (PK) of larsucosterol (DUR-928 or 25HC3S) in subjects with alcohol-associated hepatitis (AH), a devastating acute...” PMID 37011138 ↗ Apr 2023 |
| Known as | 25HC3S | “This study is to evaluate the safety and pharmacokinetics (PK) of larsucosterol (DUR-928 or 25HC3S) in subjects with alcohol-associated hepatitis (AH), a devastating acute...” PMID 37011138 ↗ Apr 2023 |
| Known as | DUR 928 | “This study is to evaluate the safety and pharmacokinetics (PK) of larsucosterol (DUR-928 or 25HC3S) in subjects with alcohol-associated hepatitis (AH), a devastating acute...” PMID 37011138 ↗ Apr 20236“* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.” NCT03917407 ↗ |
| Known as | DUR-928 sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802158 ↗ |
| Known as | DV-928 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802158 ↗ |
| Known as | DV-928 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802158 ↗ |
| Known as | LARSUCOSTEROL SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802158 ↗ |
| Known as | Sodium larsucosterol | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802158 ↗ |
| Action | Inhibit | “DNA methyltransferase inhibitor” PMID 39873544 ↗ Jan 2025 |
| Modality | Small molecule | — CHEMBL4802158 ↗ |
| Route | Oral | “oral suspension daily for 28 days” NCT03394781 ↗ |